NATERA INC (Common Stock) – ticker 45E (NTRA)
Summary
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
NATERA INC (Common Stock) – ticker 45E Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 2,955 | $582,031.24 | $811,193.6 | $229,162.36 | 39.37% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,231 | $207,514.11 | $337,928.7 | $130,414.59 | 62.85% |
| CE Curtis Ellergodt Rothschild Investment LLC | 2,564 | $450,752.64 | $703,858 | $253,105.36 | 56.15% |
| WH William Herlihy RESOURCES MANAGEMENT Corp. /CT/ /ADV | 6,671 | $1.07M | $1.83M | $757,462.7 | 70.54% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 15,688 | $1.61M | $4.33M | $2.72M | 169.26% |
NATERA INC (Common Stock) – ticker 45E Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Mark Massaro BTIG | 7 | $1,394.19 | $1,941.89 | $547.7 | 39.28% |
NATERA INC (Common Stock) – ticker 45E (NTRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NATERA INC (Common Stock) – ticker 45E ever had a stock split?
NATERA INC (Common Stock) – ticker 45E Profile
| Professional Services Industry | Industrials Sector | Steven Leonard Chapman CEO | NASDAQ (NGS) Exchange | 632307104 CUSIP |
| US Country | 6,140 Employees | - Last Dividend | - Last Split | 2 Jul 2015 IPO Date |
Overview
Natera, Inc. is a diagnostics company that focuses on developing and commercializing a range of molecular testing services on a global scale. The company's comprehensive portfolio includes tests for prenatal screening, carrier screening, genetic conditions, cancer profiling, and organ transplant rejection, among others. Founded in 2003, Natera is based in Austin, Texas and operates worldwide, selling its products through a direct sales force as well as a network of laboratory and distribution partners. The company also engages in strategic partnerships, such as with BGI Genomics Co., Ltd. and Foundation Medicine, Inc., to further expand its offerings in next-generation sequencing (NGS)-based genetic testing assays and personalized cancer monitoring tests.
Products and Services
- Panorama: A non-invasive prenatal test for detecting chromosomal abnormalities in fetuses, including in twin pregnancies.
- Horizon: A carrier screening test designed for individuals and couples to identify if they carry genetic variations that can lead to certain genetic conditions.
- Vistara: A single-gene non-invasive prenatal test that screens for 25 single-gene disorders responsible for severe skeletal, cardiac, and neurological conditions.
- Spectrum: Preimplantation genetic tests for couples undergoing in vitro fertilization (IVF) to help ensure the health of their future child.
- Anora: A test that analyzes miscarriage tissue to determine the genetic cause of a miscarriage in women.
- Empower: A hereditary cancer screening test to assess the risk of developing cancer based on genetic predisposition.
- Non-Invasive Prenatal Paternity: A product that allows couples to establish paternity for their child before birth using non-invasive methods.
- Signatera: A circulating tumor DNA (ctDNA) blood test used for assessing molecular residual disease and monitoring for cancer recurrence in previously diagnosed patients.
- Altera: A comprehensive genomic profiling test performed on tissue samples to guide cancer treatment decisions.
- Prospera: A test that assesses active rejection in patients who have undergone kidney, heart, or lung transplants to ensure successful organ acceptance.
- Renasight: A kidney gene panel test designed to inform patients of their risks of developing various kidney diseases.
- Constellation: A cloud-based software product that allows laboratory customers to access Natera's algorithms and bioinformatics through the cloud for test validation and launch.
